卡瑞丽珠长期治疗后发生大疱性类天疱疮一例

Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer:a case report

免疫检查点抑制剂(Immune Checkpoint inhibitors, ICI)为肿瘤的治疗带来了颠覆性的改革,但同时也导致较多免疫相关不良事件(immune-related adverse events, irAE)的发生。其中,大疱性类天疱疮(bullous pemphigoid, BP)是一种罕见的irAE,主要表现为红斑基础上出现水疱,疱壁紧张。本文报道1例发生于卡瑞丽珠长期治疗后的大疱性类天疱疮,并对ICI引起BP的诊断及治疗策略进行总结。

Immune checkpoint inhibitors(ICIs)have brought about a disruptive change in the treatment of tumours,but have also led to a higher incidence of immune-related adverse events(irAEs).Among them,bullous pemphigoid(BP)is a rare irAE,which is mainly manifested by blisters with tense blister based on erythema.In this paper,we report a case of BP occurring after long-term treatment with camerelizumab and summarise the diagnosis and treatment strategy of ICI-induced BP.